Sefaxersen
Based on 1 Customer Validation
Sefaxersen (IONIS-FB-LRx) is a specific antisense oligonucleotide (ASO) targeting complement factor B (CFB). Sefaxersen effectively reduces circulating levels of CFB. Sefaxersen can be used for geographic atrophy (GA) research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.46%
- CAS 番号: 2272975-74-1
- 分子量:9056.30
-
保管条件:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
生物活性
Complement factor B (CFB)[1]
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 2272975-74-1
-
性状 Solid
-
分子量 9056.30
-
Color White to off-white
-
SMILES
[Sefaxersen]
-
別名
IONIS-FB-LRx; RG6299; ISIS 696844
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
純度とドキュメンテーション
-
データシート (267 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2242 KB)
参考文献
[1]. Dreismann AK, et al. Gene targeting as a therapeutic avenue in diseases mediated by the complement alternative pathway. Immunol Rev. 2022 Nov 12. [Content Brief]
[2]. Mahmoudzadeh R, et al. Emerging treatments for geographic atrophy in age-related macular degeneration. Curr Opin Ophthalmol. 2021 May 1;32(3):294-300. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)